The aim of this study is to evaluate thoracic mobility, posture, functional capacity, and respiratory rate in children aged 8-14 years who play wind instruments and to compare these findings with those of their peers who do not play wind instruments. In line with this primary objective, the study seeks to comprehensively investigate the potential biomechanical and physiological adaptations associated with playing wind instruments in the context of childhood music education, with a particular focus on chest wall mobility, postural alignment, respiratory efficiency, and functional capacity.
The novelty of this study lies in being the first to adopt a holistic perspective to examine the effects of wind instrument playing on the postural and cardiorespiratory systems during the sensitive developmental period of 8-14 years, which is known to be highly responsive to biomechanical adaptations. By addressing this understudied age group, the study aims to fill an important gap in the existing literature.
Who can participate
Age range
8 Years – 14 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Aged 8-14 years and enrolled in primary or middle school
* Having regularly played the flute or melodica for at least one year (≥2 days/week, ≥20 minutes/day)
* For the control group, no prior experience with wind instruments during the previous year
* Absence of any diagnosed cardiopulmonary, neurological, or musculoskeletal conditions
* Giving written parent informed consent
Exclusion Criteria:
* History of an acute respiratory tract infection within the past week
* A diagnosis or history of allergic asthma or other chronic respiratory disease
* Presence of chest wall abnormalities (e.g., barrel chest)
* A diagnosed scoliosis deformity
* A diagnosis or history of developmental delay or neuromotor disorders
* Any cognitive or communication impairment that could interfere with participation in the study
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Thoracic Mobility Assessment
Timeframe: Both groups will be assessed once. There will be no intervention. All participants' measurements will be completed by May 2026.